(Bloomberg) -- Novartis AG reported first-quarter earnings that beat analysts’ estimates even after losing patent protection on its best-selling cancer medicine Gleevec.
Profit fell to $1.17 a share, excluding some items, the Basel, Switzerland-based company said Thursday in a statement. Analysts estimated $1.15, according to data compiled by Bloomberg. Sales declined 3 percent to $11.6 billion, missing analysts’ average projection.
To contact the reporter on this story: Johannes Koch in Berlin at firstname.lastname@example.org. To contact the editors responsible for this story: Chitra Somayaji at email@example.com, Kristen Hallam
©2016 Bloomberg L.P.